Table 1 Baseline characteristics and mean GH dose during two-year treatment period for total and pre-pubertal patient population by indication
Children with IGHD | Children born SGA | Children with ISS | Children with MPHD | |||||
|---|---|---|---|---|---|---|---|---|
Total | Pre-pubertal | Total | Pre-pubertal | Total | Pre-pubertal | Total | Pre-pubertal | |
Total N (pre-pubertal % of total indication) | 3,298 | 1,120 (34%) | 678 | 434 (64%) | 334 | 76 (23%) | 272 | 165 (61%) |
Male gender, N (%) | 2,444 (74%) | 778 (70%) | 396 (58%) | 274 (63%) | 240 (72%) | 59 (78%) | 171 (63%) | 106 (64%) |
Mean chronological age ± SD (years) | 10.2 ± 3.6 | 6.5 ± 2.8 | 7.9 ± 3.2 | 6.1 ± 2.1 | 10.9 ± 2.9 | 7.1 ± 2.3 | 7.9 ± 4.9 | 4.8 ± 3.5 |
Mean height SDS ± SD | −2.3 ± 1.0 | −2.7 ± 1.0 | −3.1 ± 0.9 | −3.3 ± 0.9 | −2.3 ± 0.8 | −2.6 ± 0.9 | −2.0 ± 1.5 | −2.3 ± 1.6 |
Mean bone age delay from chronological age ± SD (years) [N] | −1.8 ± 1.4 [2,419] | −1.9 ± 1.3 [703] | −1.6 ± 1.4 [430] | −1.6 ± 1.2 [266] | −1.7 ± 1.5 [294] | −1.9 ± 1.4 [65] | −1.7 ± 1.8 [137] | −1.3 ± 1.7 [63] |
Mean IGF-I SDS ± SD [N] | −1.8 ± 1.7 [2,784] | −1.4 ± 1.4 [890] | −0.7 ± 1.6 [434] | −0.5 ± 1.4 [276] | −1.6 ± 1.7 [308] | −1.2 ± 1.4 [66] | −1.9 ± 2.2 [222] | −1.4 ± 1.9 [133] |
Mean GH dose during two-year treatment period ± SD (mg/kg/day) [N] | 0.042 ± 0.013 [3,272] | 0.038 ± 0.011 [1,110] | 0.042 ± 0.013 [678] | 0.041 ± 0.013 [434] | 0.049 ± 0.012 [334] | 0.046 ± 0.011 [76] | 0.036 ± 0.013 [268] | 0.035 ± 0.011 [163] |